MU-MA402C

MU-MA402C is an autologous T-cell receptor (TCR) engineered T-cell therapy targeting the melanoma-associated antigen A4 (MAGE-A4) in the context of HLA-A*02:01. Developed by researchers at Mie University in Japan, it is designed to treat unresectable, advanced, or recurrent solid tumors that express the MAGE-A4 protein. The therapy involves the genetic modification of a patient's own T cells to express a specific TCR that recognizes the MAGE-A4 peptide-HLA complex. This treatment is typically administered following lymphodepleting chemotherapy with fludarabine and cyclophosphamide to facilitate the expansion and persistence of the infused engineered cells. MAGE-A4 is a cancer-testis antigen frequently overexpressed in various malignancies, including esophageal, lung, and head and neck cancers, making it a viable target for adoptive cell therapy.